[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555843":3},{"organization":4,"outcomesModule":7,"designInfo":41,"detailedDescription":38,"studyPopulation":43,"armGroups":44,"interventions":49,"overallOfficials":38,"centralContacts":54,"locations":60,"responsibleParty":77,"collaborators":38,"id":79,"slug":38,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":80,"sex":85,"minAge":86,"maxAge":38,"enrollmentInfo":87,"targetDuration":38,"studyType":90,"phases":38,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":63,"whyStopped":38,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"Institut Claudius Regaud","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":38},[9],{"measure":10,"description":11,"timeFrame":12},"The primary endpoint is defined as the rate of patients meeting the acceptability criteria for onco-sexology management.","This rate corresponds to the ratio of the number of patients meeting the acceptability criteria to the total number of patients included.\n\nAcceptability is defined when the following two criteria are validated:\n\n* Completion of onco-sexology consultations 2 and 3 (at 3 and 12 months after cancer treatment)\n* Patient satisfaction ≥ 3 on a numerical scale from 1 to 5.","14 months for each patient",[14,17,20,23,26,29,32,36,39],{"measure":15,"description":16,"timeFrame":12},"For the patients: Patients' sexual satisfaction will be assessed using the specific scale of the EORTC QLQSHQ-C22 questionnaire.","The score, which ranges from 0 to 100, is determined according to the algorithm published by the EORTC, based on answers to 8 questions. This is a self-administered questionnaire validated in French",{"measure":18,"description":19,"timeFrame":12},"For the patients: Quality of life will be assessed using the EORTC QLQ-C30 questionnaire and the disease-specific QLQ-H&N43 questionnaire.","These are self-administered questionnaires validated in French.",{"measure":21,"description":22,"timeFrame":12},"For the patients: The female sexual function (desire, arousal, pain, lubrication, satisfaction, orgasm).","The FSFI (Female Sexual Function Index) is a self-administered questionnaire validated in French. It comprises 19 items studying 6 dimensions of female sexual function (desire, arousal, pain, lubrication, satisfaction, orgasm) which make up an overall score of between 2 and 36.",{"measure":24,"description":25,"timeFrame":12},"For the patients: The ability to have sexual intercourse by considering several domains (erections, ejaculations, desire and satisfaction).","The MSHQ (Male Sexual Health Questionnaire) is a self-questionnaire validated in French which assesses the ability to have sexual intercourse by considering several domains (erections, ejaculations, desire and satisfaction).",{"measure":27,"description":28,"timeFrame":12},"For the patients: The impact of (pharyngo)laryngectomy totale on the couple's relationship.","It will be assessed using a descriptive analysis (marital status before and after cancer treatment, stability, strengthening or deterioration of the couple's relationship).",{"measure":30,"description":31,"timeFrame":12},"For the patients: Satisfaction or dissatisfaction with the onco-sexology consultation.","It will be assessed using a Likert scale. This type of scale was developed to measure attitudes and opinions (Rensis Likert 'A Technique for the Measurement of Attitudes', Archives of Psychology, vol.140, 1932, p. 1-55).",{"measure":33,"description":34,"timeFrame":35},"For the partner: - The rate of partners verifying the acceptability criteria for onco-sexology management is defined by the ratio of the number of partners verifying the acceptability criteria to the total number of partners included.","The definition of acceptability is the same as for the primary endpoint.","14 months for each partner",{"measure":37,"description":38,"timeFrame":35},"For the partner: The impact of the (pharyngo)laryngectomy totale on the couple's relationship will be assessed using a descriptive analysis (stability, reinforcement or deterioration of the couple's life).",null,{"measure":40,"description":38,"timeFrame":35},"For the partner: Satisfaction or dissatisfaction with the onco-sexology consultation will be assessed using a Likert scale.",{"allocation":38,"interventionModel":38,"interventionModelDescription":38,"primaryPurpose":38,"observationalModel":6,"timePerspective":42,"maskingInfo":38},"PROSPECTIVE","Patients with cancer (ORL) treated by laryngectomy.",[45],{"label":46,"type":38,"description":38,"interventionNames":47},"Patients with cancer (ORL) treated by laryngectomy",[48],"Other: In this research, the procedure under study is represented:",[50],{"type":6,"name":51,"description":52,"armGroupLabels":53,"otherNames":38},"In this research, the procedure under study is represented:","* On the one hand, by carrying out sexology consultations which consist of individual interviews with a qualified sexologist nurse.\n* Secondly, questionnaires to assess quality of life and sexual function, to be completed by patients during standard follow-up consultations; and a questionnaire on satisfaction with sexological follow-up, to be completed by patients and their partners (if applicable) during the last standard follow-up consultation.",[46],[55],{"name":56,"role":57,"phone":58,"phoneExt":38,"email":59},"Julienne VIDAL","CONTACT","05 31 15 51 36","vidal.julienne@iuct-oncopole.fr",[61],{"facility":62,"status":63,"city":64,"state":38,"zip":38,"country":65,"countryCode":66,"cosmosGeoPoint":67,"geoPoint":72,"contacts":73},"IUCT-O","RECRUITING","Toulouse","France","FR",{"type":68,"coordinates":69},"Point",[70,71],1.44367,43.60426,{"lat":71,"lon":70},[74],{"name":75,"role":57,"phone":58,"phoneExt":38,"email":76},"Josiane MENARD","menard.josiane@iuct-oncopole.fr",{"type":78,"investigatorFullName":38,"investigatorTitle":38,"investigatorAffiliation":38,"oldNameTitle":38,"oldOrganization":38},"SPONSOR","100555843",false,"NCT06517355","Acceptability and Benefits of an Onco-sexology Program for Laryngectomy Patients and Their Partners","ABSENS","Inclusion Criteria:\n\nFor patients:\n\n1. Patient to be treated for ORL cancer by total (pharyngo)laryngectomy\n2. Patient WHO 0-1-2\n3. Age greater than or equal to 18 years\n4. Patient who has not objected to participation in the study.\n\nFor partners (if applicable) :\n\n1. Age greater than or equal to 18 years\n2. Subject who has not objected to participation in the study.\n\nExclusion Criteria:\n\nFor patients:\n\n1. Patient with another co-existing malignant disease at the time of inclusion.\n2. Any psychological, familial, geographical or sociological condition that does not allow for compliance with the medical follow-up and\u002For procedures foreseen in the study protocol.\n3. Patients deprived of their liberty or under legal protection (guardianship and tutorship, safeguard of justice).\n\nFor partners (if applicable):\n\n1\\. Patients deprived of their liberty or under legal protection (guardianship and tutorship, safeguard of justice).","ALL","18 Years",{"count":88,"type":89},45,"ESTIMATED","OBSERVATIONAL","Single-centre prospective pilot study designed to demonstrate the acceptability of onco-sexology management for laryngectomy patients and their partners in order to improve their perception of their intimate life. This is a non-interventional study (category 3 Loi Jardé), which will not result in any change in patient management. All procedures will be carried out in accordance with standard practice.\n\nPatients will be followed for 14 months.",[93],"ORL Cancer",[95,96,97],"ORL cancer","Onco-sexology care","Laryngectomy","2026-06-12",{"date":100,"type":101},"2026-06-16","ACTUAL",{"date":103,"type":101},"2024-07-30",{"date":105,"type":89},"2028-03",{"name":5,"class":6},1]